GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (STU:HQE1) » Definitions » Institutional Ownership

CytoSorbents (STU:HQE1) Institutional Ownership : 11.70% (As of Jun. 09, 2024)


View and export this data going back to 2011. Start your Free Trial

What is CytoSorbents Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CytoSorbents's institutional ownership is 11.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CytoSorbents's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CytoSorbents's Float Percentage Of Total Shares Outstanding is 97.18%.


CytoSorbents Institutional Ownership Historical Data

The historical data trend for CytoSorbents's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Institutional Ownership Chart

CytoSorbents Historical Data

The historical data trend for CytoSorbents can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 16.55 15.43 12.46 12.37 12.46 12.47 12.43 12.00 11.70 11.70

CytoSorbents Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


CytoSorbents (STU:HQE1) Business Description

Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

CytoSorbents (STU:HQE1) Headlines

No Headlines